Antiangiogenic therapy using nanotechnological-based delivery system

Drug Discovery Today

Volumn 16, Issue 5-6, 2011, Pages 188-202

  Kanwar, Jagat R ^a   Mahidhara, Ganesh ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; B7 ANTIGEN; CAPSAICIN; CELL PENETRATING PEPTIDE; CURCUMIN; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; LACTOFERRIN; MICRORNA; NANOCARRIER; NANOPARTICLE; NEEM OIL; OLIGOPEPTIDE; PACLITAXEL; PEGAPTANIB; PEPTIDE APTAMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SMALL INTERFERING RNA; STIMALMER; TAMOXIFEN; TANESPIMYCIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN; ZINOSTATIN;

ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; DIABETIC RETINOPATHY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG INHIBITION; ENZYME METABOLISM; GENE TARGETING; GENETIC RECOMBINATION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INTERNALIZATION; MAMMAL CELL; METASTASIS; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; THYMUS LYMPHOMA; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; NEOPLASTIC STEM CELLS; RNA;

EID: 79952440644     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.01.007     Document Type: Review

References (191)

1. S. Aznavoorian Molecular aspects of tumor cell invasion and metastasis Cancer 71 1993 1368 1383 (Pubitemid 23054933)
2. S.L. Harris, and A.J. Levine The p53 pathway: positive and negative feedback loops Oncogene 24 2005 2899 2908 (Pubitemid 40638098)
3. U. Cavallaro, and G. Christofori Molecular mechanisms of tumor angiogenesis and tumor progression J. Neuro-Oncol. 50 2000 63 70 (Pubitemid 32166291)
4. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat. Med. 1 1995 27 31
5. T.L. Haas Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle Am. J. Physiol. Heart Circ. Physiol. 279 2000 H1540 1547
6. J.F. Kerr Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br. J. Cancer 26 1972 239 257
7. A.G. Knudson Jr Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. U. S. A. 68 1971 820 823
8. G.E. O'Rourke, and A.O. Ellem John Kerr and apoptosis Med. J. Aust. 173 2000 616 617 (Pubitemid 32041102)
9. C.B. Thompson Apoptosis in the pathogenesis and treatment of disease Science 267 1995 1456 1462
10. J.M. Zapata A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains J. Biol. Chem. 276 2001 24242 24252
11. P.H. Krammer CD95s deadly mission in the immune system Nature 407 2000 789 795
12. H. Wajant The Fas signaling pathway: more than a paradigm Science 296 2002 1635 1636 (Pubitemid 34579146)
13. D. Hockenbery Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 348 1990 334 336 (Pubitemid 120029101)
14. C. Scaffidi Two CD95 (APO-1/Fas) signaling pathways EMBO J. 17 1998 1675 1687 (Pubitemid 28119121)
15. F. Li Survivin study: what is the next wave? J. Cell Physiol. 197 2003 8 29 (Pubitemid 37486223)
16. F. Li, and X. Ling Survivin study: an update of 'what is the next wave'? J. Cell Physiol. 208 2006 476 486 (Pubitemid 44141872)
17. A. Yagihashi Detection of autoantibodies to survivin and livin in sera from patients with breast cancer Clin. Chim. Acta 362 2005 125 130 (Pubitemid 41597098)
18. J.R. Kanwar Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy J. Natl. Cancer Inst. 93 2001 1541 1552 (Pubitemid 32998483)
19. G. Jiang Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma Cancer Biol. Ther. 5 2006 435 440
20. F. Paduano Silencing of suvivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17- demethoxygeldanamycin in human prostate cancer cells Mol. Cancer Ther. 5 2006 179 186
21. Kanwar, J.R. et al. (2010) Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 20, 1723-1737
22. C.H. Cheung Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells Mol. Cancer 9 2010 77
23. J. Folkman How the field of controlled-release technology began, and its central role in the development of angiogenesis research Biomaterials 11 1990 615 618
24. J. Folkman, and R. Kalluri Cancer without disease Nature 427 2004 787 (Pubitemid 38297724)
25. J. Folkman New perspectives in clinical oncology from angiogenesis research Eur. J. Cancer 32A 1996 2534 2539
26. P.H. Maxwell Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc. Natl. Acad. Sci. U. S. A. 94 1997 8104 8109 (Pubitemid 27343784)
27. K. Kuwabara Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells Proc. Natl. Acad. Sci. U. S. A. 92 1995 4606 4610
28. G.N. Naumov Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch Cell Cycle 5 2006 1779 1787 (Pubitemid 44435320)
29. X. Sun Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression Cancer Gene Ther. 8 2001 719 727 (Pubitemid 32983128)
30. H. Jiang Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice Cancer Invest. 28 2010 74 84
31. M.K. Brunckhorst Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis Cancer Res. 70 2010 7283 7293
32. Y. Lee MicroRNA maturation: stepwise processing and subcellular localization EMBO J. 21 2002 4663 4670 (Pubitemid 34984353)
33. Y. Lee The nuclear RNase III Drosha initiates microRNA processing Nature 425 2003 415 419 (Pubitemid 37187272)
34. R.I. Gregory, and R. Shiekhattar MicroRNA biogenesis and cancer Cancer Res. 65 2005 3509 3512 (Pubitemid 40616320)
35. R. Yi Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs Genes Dev. 17 2003 3011 3016 (Pubitemid 38040764)
36. V. Ambros microRNAs: tiny regulators with great potential Cell 107 2001 823 826 (Pubitemid 34084973)
37. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355 (Pubitemid 39265675)
38. R.C. Lee The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 75 1993 843 854 (Pubitemid 24014542)
39. B.J. Reinhart The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans Nature 403 2000 901 906 (Pubitemid 30130993)
40. J.R. Kanwar MicroRNA in human cancer and chronic inflammatory diseases Front. Biosci. 2 2010 1113 1126
41. A.E. Pasquinelli Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA Nature 408 2000 86 89
42. S.M. Johnson RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647 (Pubitemid 40343076)
43. G.A. Calin Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc. Natl. Acad. Sci. U. S. A. 99 2002 15524 15529 (Pubitemid 35403967)
44. Y. Akao let-7 microRNA functions as a potential growth suppressor in human colon cancer cells Biol. Pharm. Bull. 29 2006 903 906
45. M.Z. Michael Reduced accumulation of specific microRNAs in colorectal neoplasia Mol. Cancer Res. 1 2003 882 891 (Pubitemid 37288707)
46. S. Volinia A microRNA expression signature of human solid tumors defines cancer gene targets Proc. Natl. Acad. Sci. U. S. A. 103 2006 2257 2261 (Pubitemid 43271657)
47. W. Tam Avian bic, a gene isolated from a common retroviral site in avian leukosis virus-induced lymphomas that encodes a noncoding RNA, cooperates with c-myc in lymphomagenesis and erythroleukemogenesis J. Virol. 76 2002 4275 4286 (Pubitemid 34309563)
48. A. Ota Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma Cancer Res. 64 2004 3087 3095 (Pubitemid 38581408)
49. J.A. Chan MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Res. 65 2005 6029 6033 (Pubitemid 40994386)
50. P.M. Voorhoeve A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors Cell 124 2006 1169 1181
51. K.H. Plate Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 1992 845 848
52. D. Shweiki Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 359 1992 843 845
53. G.L. Semenza Transcriptional regulation by hypoxia-inducible factor 1: molecular mechanisms of oxygen homeostasis Trends Cardiovasc. Med. 6 1996 151 157 (Pubitemid 26256220)
54. R. Kulshreshtha A microRNA signature of hypoxia Mol. Cell. Biol. 27 2007 1859 1867
55. P. Fasanaro MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-A3 J. Biol. Chem. 283 2008 15878 15883
56. D.Y. Lee MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression Proc. Natl. Acad. Sci. U. S. A. 104 2007 20350 20355
57. A. Kuehbacher Role of dicer and drosha for endothelial microRNA expression and angiogenesis Circ. Res. 101 2007 59 68 (Pubitemid 47094624)
58. S. Wang The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis Dev. Cell 15 2008 261 271
59. J.E. Fish miR-126 regulates angiogenic signaling and vascular integrity Dev. Cell 15 2008 272 284
60. K. Kondo, and W.G. Kaelin Jr The von Hippel-Lindau tumor suppressor gene Exp. Cell Res. 264 2001 117 125 (Pubitemid 32989086)
61. X. Sun Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha Gene Ther. 10 2003 2081 2089 (Pubitemid 37483650)
62. A.K. Ghosh Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells Blood 113 2009 5568 5574
63. C. Tuerk, and L. Gold Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 249 1990 505 510
64. J.R. Kanwar Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases Nanomedicine 5 2010 1435 1445
65. L.C. Griffin In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits Blood 81 1993 3271 3276 (Pubitemid 23172909)
66. M. Blind Cytoplasmic RNA modulators of an inside-out signal-transduction cascade Proc. Natl. Acad. Sci. U. S. A. 96 1999 3606 3610 (Pubitemid 29168957)
67. A.A. Moshfeghi, and C.A. Puliafito Pegaptanib sodium for the treatment of neovascular age-related macular degeneration Exp. Opin. Invest. Drugs 14 2005 671 682 (Pubitemid 40790287)
68. J. Mi RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin Mol. Ther. 16 2008 66 73
69. S. Sarraf-Yazdi Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer J. Surg. Res. 146 2008 16 23 (Pubitemid 351442931)
70. H. Li Therapeutic effects of matrine on primary and metastatic breast cancer Am. J. Chin. Med. 38 2010 1 16
71. J.R. Kanwar Requirements for ICAM-1 immunogene therapy of lymphoma Cancer Gene Ther. 10 2003 468 476 (Pubitemid 36667133)
72. J.R. Kanwar 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy Immunol. Cell. Biol. 86 2008 277 288 (Pubitemid 351430811)
73. A. Fire Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811 (Pubitemid 28099681)
74. N.J. Caplen Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems Proc. Natl. Acad. Sci. U. S. A. 98 2001 9742 9747 (Pubitemid 32769374)
75. S.M. Elbashir Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498 (Pubitemid 32494397)
76. P.J. Paddison Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells Genes Dev. 16 2002 948 958 (Pubitemid 34408544)
77. S. Bivalkar-Mehla Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system Virus Res. 155 2011 1 9
78. A. de Fougerolles Interfering with disease: a progress report on siRNA-based therapeutics Nat. Rev. Drug Discov. 6 2007 443 453
79. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 2006 819 829
80. L. Luo Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas Int. J. Cancer 118 2006 1823 1830 (Pubitemid 43376449)
81. X. Sun Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors Cancer Gene Ther. 12 2005 35 45 (Pubitemid 39665241)
82. X. Sun Mouse B7-H3 induces antitumor immunity Gene Ther. 10 2003 1728 1734 (Pubitemid 37121044)
83. J.R. Kanwar Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci Cancer Res. 61 2001 1948 1956 (Pubitemid 32692012)
84. J. Kanwar Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity Gene Ther. 6 1999 1835 1844 (Pubitemid 29531279)
85. C.G.A. Cheung A cell-permeable dominant-negative survivin protein as a tool to understand how survivin maintains tumour cell survival Eur. J. Cancer 4 2006 149
86. N. Kobayashi Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression J. Pharmacol. Exp. Ther. 308 2004 688 693 (Pubitemid 38134232)
87. D.W. Bartlett, and M.E. Davis Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging Nucleic Acids Res. 34 2006 322 333 (Pubitemid 43160055)
88. C.I. Wooddell Long-term RNA interference from optimized siRNA expression constructs in adult mice Biochem. Biophys. Res. Commun. 334 2005 117 127 (Pubitemid 40978514)
89. L. Zhang Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth Clin. Cancer Res. 14 2008 559 568 (Pubitemid 351226126)
90. A. Maliyekkel Cell cycle arrest drastically extends the duration of gene silencing after transient expression of short hairpin RNA Cell Cycle 5 2006 2390 2395 (Pubitemid 44785849)
91. Y. Zhang In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats J. Gene Med. 5 2003 1039 1045 (Pubitemid 40310428)
92. B.R. Meade, and S.F. Dowdy Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides Adv. Drug Deliv. Rev. 60 2008 530 536
93. G.W. Krissansen A pseudosymmetric cell adhesion regulatory domain in the beta7 tail of the integrin alpha4beta7 that interacts with focal adhesion kinase and src Eur. J. Immunol. 36 2006 2203 2214 (Pubitemid 44251765)
94. D. Schaffert, and E. Wagner Gene therapy progress and prospects: synthetic polymer-based systems Gene Ther. 15 2008 1131 1138
95. S. Zhang Cationic lipids and polymers mediated vectors for delivery of siRNA J. Control. Release 123 2007 1 10 (Pubitemid 47444388)
96. I.S. Zuhorn Gene delivery by cationic lipid vectors: overcoming cellular barriers Eur. Biophys. J. 36 2007 349 362 (Pubitemid 46626209)
97. J. Zhou, and J. Rossi Aptamer-targeted cell-specific RNA interference Silence 1 2010 4
98. D. Shangguan Identification of liver cancer-specific aptamers using whole live cells Anal. Chem. 80 2008 721 728 (Pubitemid 351206860)
99. R. Juliano Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides Nucleic Acids Res. 36 2008 4158 4171 (Pubitemid 351984831)
100. E. Levy-Nissenbaum Nanotechnology and aptamers: applications in drug delivery Trends Biotechnol. 26 2008 442 449
101. K.W. Thiel, and P.H. Giangrande Therapeutic applications of DNA and RNA aptamers Oligonucleotides 19 2009 209 222
102. J.O. McNamara 2nd Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 24 2006 1005 1015
103. T. Chu Aptamer mediated siRNA delivery Nucleic Acids Res. 34 2006 e73
104. U. Wullner Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2 Curr. Cancer Drug Targets 8 2008 554 565
105. J.P. Dassie Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors Nat. Biotechnol. 27 2009 839 849
106. E. Kawata A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro Cancer Lett. 294 2010 245 253
107. F. Pastor Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay Nature 465 2010 227 230
108. S. Baratchi Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases Curr. Nanosci. 5 2009 15 25
109. A.D. Frankel, and C.O. Pabo Cellular uptake of the tat protein from human immunodeficiency virus Cell 55 1988 1189 1193 (Pubitemid 19020071)
110. M. Green, and P.M. Loewenstein Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein Cell 55 1988 1179 1188 (Pubitemid 19020070)
111. H. Nagahara Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration Nat. Med. 4 1998 1449 1452 (Pubitemid 28553472)
112. E. Vives A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus J. Biol. Chem. 272 1997 16010 16017 (Pubitemid 27265584)
113. G. Elliott, and P. O'Hare Intercellular trafficking and protein delivery by a herpesvirus structural protein Cell 88 1997 223 233 (Pubitemid 28015871)
114. K. Han Efficient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins Mol. Cells 10 2000 728 732
115. M. Pooga Cell penetration by transportan FASEB J. 12 1998 67 77 (Pubitemid 28060272)
116. D. Derossi The third helix of the Antennapedia homeodomain translocates through biological membranes J. Biol. Chem. 269 1994 10444 10450 (Pubitemid 24198241)
117. H. Kaneto Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide Nat. Med. 10 2004 1128 1132 (Pubitemid 39424876)
118. S.R. Schwarze In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572 (Pubitemid 29420581)
119. V. Del Gaizo, and R.M. Payne A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta Mol. Ther. 7 2003 720 730 (Pubitemid 36790248)
120. H. Harada Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells Cancer Res. 62 2002 2013 2018 (Pubitemid 34408445)
121. G.P. Dietz, and M. Bahr Delivery of bioactive molecules into the cell: the Trojan horse approach Mol. Cell. Neurosci. 27 2004 85 131 (Pubitemid 39370094)
122. M. Zorko, and U. Langel Cell-penetrating peptides: mechanism and kinetics of cargo delivery Adv. Drug Deliv. Rev. 57 2005 529 545 (Pubitemid 40255559)
123. S. Futaki Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery J. Biol. Chem. 276 2001 5836 5840
124. J.B. Rothbard Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation Nat. Med. 6 2000 1253 1257
125. T.J. Davidson Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation J. Neurosci. 24 2004 10040 10046 (Pubitemid 39492027)
126. A. Muratovska, and M.R. Eccles Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells FEBS Lett. 558 2004 63 68 (Pubitemid 38167411)
127. J.J. Turner RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA Blood Cells Mol. Dis. 38 2007 1 7 (Pubitemid 44960863)
128. M.C. Morris A peptide carrier for the delivery of biologically active proteins into mammalian cells Nat. Biotechnol. 19 2001 1173 1176 (Pubitemid 33115705)
129. S.A. Moschos Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity Bioconjug. Chem. 18 2007 1450 1459 (Pubitemid 47464052)
130. S. Deshayes Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis Biochemistry 43 2004 1449 1457 (Pubitemid 38200550)
131. P. Lundberg Delivery of short interfering RNA using endosomolytic cell-penetrating peptides FASEB J. 21 2007 2664 2671 (Pubitemid 47372734)
132. F. Simeoni Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells Nucleic Acids Res. 31 2003 2717 2724 (Pubitemid 37442116)
133. S. Veldhoen Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect Nucleic Acids Res. 34 2006 6561 6573 (Pubitemid 46017951)
134. P. Kumar T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 134 2008 577 586
135. P. Kumar Transvascular delivery of small interfering RNA to the central nervous system Nature 448 2007 39 43 (Pubitemid 47037001)
136. Y.H. Wang An intracellular delivery method for siRNA by an arginine-rich peptide J. Biochem. Biophys. Methods 70 2007 579 586
137. L.N. Johnson Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea Mol. Ther. 16 2008 107 114
138. L. Crombez A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells Mol. Ther. 17 2009 95 103
139. B. Albarran A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells Protein Eng. Des. Sel. 18 2005 147 152 (Pubitemid 40638065)
140. M.C. Morris A new peptide vector for efficient delivery of oligonucleotides into mammalian cells Nucleic Acids Res. 25 1997 2730 2736 (Pubitemid 27299785)
141. M. Mie Intracellular delivery of antibodies using TAT fusion protein A Biochem. Biophys. Res. Commun. 310 2003 730 734 (Pubitemid 37188681)
142. J.C. Mai Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate J. Biol. Chem. 277 2002 30208 30218
143. C. Oubridge Crystal structure at 1.92 resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin Nature 372 1994 432 438
144. K.B. Hall, and W.T. Stump Interaction of N-terminal domain of U1A protein with an RNA stem/loop Nucleic Acids Res. 20 1992 4283 4290
145. J.B. Delehanty Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery Bioconjug. Chem. 17 2006 920 927 (Pubitemid 44162609)
146. B.C. Lagerholm Multicolor coding of cells with cationic peptide coated quantum dots Nano Lett. 4 2004 2019 2022
147. J.R. Kanwar Recent advances in nanoneurology for drug delivery to the brain Curr. Nanosci. 5 2009 441 448
148. Z. Xin Hua Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs J. Control. Release 29 1994 239 252
149. X.H. Zhou, and A. Li Wan Po Comparison of enzyme activities of tissues lining portals of absorption of drugs: species differences Int. J. Pharm. 70 1991 271 283
150. K. Morimoto Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue Pharm. Res. 8 1991 1175 1179
151. R.A. Conradi The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability Pharm. Res. 9 1992 435 439
152. M.H. Shah, and A. Paradkar Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme Int. J. Pharm. 294 2005 161 171 (Pubitemid 40462332)
153. V.P. Torchilin Immobilization of enzymes on slowly soluble carriers J. Biomed. Mater. Res. 11 1977 223 235 (Pubitemid 8059795)
154. A. Prokop Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application Biotechnol. Bioeng. 78 2002 459 466 (Pubitemid 34712366)
155. O. Benny An orally delivered small-molecule formulation with antiangiogenic and anticancer activity Nat. Biotechnol. 26 2008 799 807 (Pubitemid 351961454)
156. G. Cevc Lipid vesicles and other colloids as drug carriers on the skin Adv. Drug Deliv. Rev. 56 2004 675 711 (Pubitemid 38326939)
157. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 (Pubitemid 44286001)
158. S. Foley Cellular localisation of a water-soluble fullerene derivative Biochem. Biophys. Res. Commun. 294 2002 116 119 (Pubitemid 34687223)
159. C.R. Martin, and P. Kohli The emerging field of nanotube biotechnology Nat. Rev. Drug Discov. 2 2003 29 37 (Pubitemid 37361622)
160. M. Rawat Nanocarriers: promising vehicle for bioactive drugs Biol. Pharm. Bull. 29 2006 1790 1798 (Pubitemid 44338396)
161. M. Rawat Development and in vitro evaluation of alginate gel-encapsulated, chitosan-coated ceramic nanocores for oral delivery of enzyme Drug Dev. Ind. Pharm. 34 2008 181 188 (Pubitemid 351317140)
162. Mahidhara, G. et al. A novel nanoplatform for oral delivery of anti-cancer biomacromolecules. Int. J. Nanotechnol. (in press)
163. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
164. D. Peer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 (Pubitemid 350223348)
165. S. Sengupta Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 2005 568 572 (Pubitemid 41112931)
166. H. Devalapally Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
167. M. Das, and S.K. Sahoo Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy Acta Biomater. 7 2011 355 369
168. M.H. Lameiro Incorporation of a model protein into chitosan-bile salt microparticles Int. J. Pharm. 312 2006 119 130
169. J.L. Cleland Protein delivery from biodegradable microspheres Pharm. Biotechnol. 10 1997 1 43
170. A.K. Cherian Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin Drug Dev. Ind. Pharm. 26 2000 459 463 (Pubitemid 30207720)
171. R. Bawa NanoBiotech 2008: exploring global advances in nanomedicine Nanomedicine 5 2009 5 7
172. S. Baratchi Survivin: a target from brain cancer to neurodegenerative disease Crit. Rev. Biochem. Mol. Biol. 45 2010 535 554
173. Kanwar, R.K. et al. Preparation and characterization of SurR9-C84A loaded polymeric nano carriers for oral delivery in colon cancer Nano Med. (in press)
174. C.H.A. Cheung A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy Cancer Cell Int. 10 2010 36
175. T.H. Thai Regulation of the germinal center response by microRNA-155 Science 316 2007 604 608
176. E. Tili Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-{alpha} stimulation and their possible roles in regulating the response to endotoxin shock J. Immunol. 179 2007 5082 5089
177. Y. Chen, and D.H. Gorski Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5 Blood 111 2008 1217 1226 (Pubitemid 351213403)
178. M. Dews Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster Nat. Genet. 38 2006 1060 1065 (Pubitemid 44325933)
179. Y. Arthanari Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr-abl fusion gene in chronic myeloid leukemia cells J. Control. Release 145 2010 272 280
180. H. Mok, and T.G. Park Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA Biopolymers 89 2008 881 888
181. T. Endoh Photo inducible RNA interference using cell permeable protein carrier Nucleic Acids Symp. Ser. 51 2007 127 128
182. S.W. Kim RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system J. Control. Release 143 2010 335 343
183. K. Tanaka Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing Int. J. Pharm. 398 2010 219 224
184. S.H. Kim VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine) Mol. Pharm. 6 2009 718 726
185. V.P. Torchilin Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs Proc. Natl. Acad. Sci. U. S. A. 100 2003 6039 6044 (Pubitemid 36576927)
186. Y. Choi Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting Chem. Biol. 12 2005 35 43 (Pubitemid 40118324)
187. B.H. Schneider Highly sensitive optical chip immunoassays in human serum Biosens. Bioelectron. 15 2000 13 22 (Pubitemid 32667454)
188. G. Hong Folate-functionalized polymeric micelle as hepatic carcinoma-targeted MRI-ultrasensitive delivery system of antitumor drugs Biomed. Microdevices 10 2008 693 700
189. S.H. Kim Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer J. Control. Release 129 2008 107 116
190. S.H. Lee Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide Biochem. Biophys. Res. Commun. 357 2007 511 516 (Pubitemid 46603160)
191. E. Kim Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex Biomaterials 31 2010 4592 4599